comprehensive -WSS

comprehensive

author：Wikipedia 2025-09-30 12:44:58 Page View：5

close-up of psoriasis on a hand. -- biotech coverage from STAT — A close-up of psoriasis on a hand. Adobe

San Francisco startup Alumis Inc. has raised $259 million in a bid to best big pharma’s work in plaque psoriasis.

Alumis announced its Series C round Wednesday and plans to move its lead drug into Phase 3 trials. Venture firm Foresite Capital, which incubated Alumis, co-led the financing with Samsara BioCapital and venBio Partners.

Alumis’ lead drug, ESK-001, is an oral medicine designed to help patients with the most common type of psoriasis by inhibiting a signaling protein called TYK2. Research has shown that the TYK2 protein plays a role in diseases where the immune system overreacts, which has made it a popular drug target in recent years.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Having children helps parents live longer, especially after age 80
Next article： The Supreme Court will review a ruling striking down a domestic violence federal gun ban

focus

DIEP, the 'gold standard' of breast reconstruction, is under threat

AdobeIn1983,Iflewhomefromcollegetobewithmymotherasshewokeupfromamastectomy.Sheoptedoutofbreastrecons

Latigo launches with $135 million for Vertex

DesmondPadhi,PharmD,interimCEO,Latigo(center),withLatigoboardchairNancyStagliano(left)andWestlakeVil

United colonoscopy coverage change 'may cost lives,' doctors say

AdobeWhengastroenterologistslearnedinMarchthatUnitedHealthcareplanstobarricademanycolonoscopiesbehin

Key Senate panel to consider PBM, drug pricing reform package

Sens.RonWydenandMikeCrapointroducedamentalhealth,PBMreformandsubstanceusepolicypackage.DrewAngerer/G